Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the appointment of Stuart Gall and Philip Rodgers as independent non-executive Directors of the Company, both with effect from 1 February 2024.
As announced in the Trading Update this morning, the Company has seen revenue growth of 7% in 2023 and an adjusted operating profit in the second half in a difficult economic environment and is positioned to deliver further growth in the future. The appointments will strengthen the Board to support these growth plans by adding additional commercial, investor relations and financial expertise. The additions to the Board take the number of non-executive directors to five; providing strengthened governance and succession for possible future rotation of Board members.
Stuart Gall is CEO of Intelligent Ultrasound, an AIM-listed medical imaging company providing one of the world’s leading ‘classroom to clinic’ ultrasound technologies. Previous appointments include joint founder and executive director of Fusion IP plc, an AIM listed university IP commercialisation company, before its purchase by IP Group plc for £103 million in 2014. Stuart has over 30 years’ experience in both small company start-ups and public companies and previously worked at British Airways plc, The Promotions Partnership Limited, Anvil Limited and Toad plc (now Journeo plc).
Nick Rodgers is currently Chair of SEHTA, one of the largest health technology membership and networking organisations in the UK supporting businesses in the health technology sector. Until 2023 Nick was Chair of Destiny Pharma plc, a developer of novel anti-infective products and chair of ZPN Energy Limited, a developer of battery storage technologies and systems for the electric vehicle market. Previously, until 2016, Nick was chairman of Oxford BioMedica plc, a pioneer of gene and cell therapy and a leader in lentiviral vector research, development and bioprocessing.
Dr Steven Powell, Chairman of Cambridge Cognition, commented:
“On behalf of the Board, I am delighted to welcome Stuart and Nick to Cambridge Cognition. Their broad expertise and deep industry experience in the healthcare and technology sectors will be extremely valuable in the next stage of Cambridge Cognition’s development now that we have integrated the two acquisitions made in 2022/23, which strengthen the Company’s product offering and cement its leading market position. We look forward to benefitting from their insights as the Board continues to lead Cambridge Cognition to profitability and accelerate and execute the Company’s growth plans.”
